In vivo PEG modification of vascular surfaces for targeted delivery

被引:14
|
作者
Deglau, Timothy E. [1 ,2 ]
Maul, Timothy M. [1 ,2 ,3 ]
Villanueva, Flordeliza S. [2 ,4 ]
Wagner, William R. [1 ,2 ,3 ,5 ]
机构
[1] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA
[2] McGowan Inst Regenerat Med, Pittsburgh, PA USA
[3] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA
[4] UPMC Cardiovasc Inst, Pittsburgh, PA USA
[5] Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA
基金
美国国家卫生研究院;
关键词
DRUG-ELUTING STENTS; MUSCLE-CELL-PROLIFERATION; POLYETHYLENE-GLYCOL; PLATELET-ADHESION; POLY(ETHYLENE GLYCOL); PROTEIN ADSORPTION; MOLECULAR BARRIERS; HYDROGEL BARRIERS; BALLOON INJURY; RESTENOSIS;
D O I
10.1016/j.jvs.2011.09.081
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Thrombosis and restenosis remain problematic for many intravascular procedures. Previously, it has been demonstrated that modifying an injured vascular surface with a protein-reactive polymer could block undesirable platelet deposition. As an added benefit, it would be advantageous if one could target therapeutics to the injured site. This study investigates a site-specific delivery system to target microspheres to vascular surfaces modified with a reactive polyethylene glycol tagged with biotin. Methods: Rabbit femoral arteries were injured with a 2F embolectomy catheter. Modification of the vascular surface was achieved using a channeled balloon catheter or small-diameter tube. Microspheres were injected intravenously through catheterization of the ear vein. Polymer modification on the injured surface and delivery of microspheres was quantified using epifluorescence microscopy at 0, 24, 48, and 72 hours. Results: Polymer modification of the vascular surface could be achieved using a channeled drug delivery catheter or small-diameter tube with similar results. Maximum polymer coverage occurred at 0 hours and decreased to 85% maximal at 24 hours, 72% at 48 hours, and 67% at 72 hours. The initial number of microspheres per mm(2) binding to modified, injured arteries was 304 versus 141 for the unmodified, damaged control (P<.01). At subsequent times, the number of adherent microspheres to modified, injured arteries decreased by 50%, 70%, and 84% at 24, 48, and 72 hours, respectively; while nonspecific binding to unmodified, injured arteries quickly decreased by 93%. Initial microsphere binding to modified, healthy arteries was 153 microspheres/mm(2) as opposed to 26 microspheres/mm(2) for the unmodified, healthy controls (P<.01). Conclusions: Chemical modification of injured vessels following intravascular procedures can be readily accomplished in vivo to create a substrate for targeted delivery systems. As a proof of concept, targeted microspheres preferentially adhered to polymer-modified surfaces as opposed to injured, unmodified, or healthy vascular surfaces. (J Vasc Surg 2012; 55: 1087-95.)
引用
收藏
页码:1087 / 1095
页数:9
相关论文
共 50 条
  • [21] Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
    Wullner, Ulrich
    Neef, Inga
    Tur, Mehmet K.
    Barth, Stefan
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (01) : 1 - 8
  • [22] MODELING TARGETED DRUG DELIVERY IN A VASCULAR NETWORK
    Liu, Yaling
    Nguyen, Kytai
    Mariyappa, Manohara
    Shah, Samar
    Tan, Jifu
    NEMB2010: PROCEEDINGS OF THE ASME FIRST GLOBAL CONGRESS ON NANOENGINEERING FOR MEDICINE AND BIOLOGY - 2010, 2010, : 363 - 364
  • [23] Vascular biology - Targeted delivery of nitric oxide
    Gross, SS
    NATURE, 2001, 409 (6820) : 577 - 578
  • [24] Targeted Vascular Drug Delivery in Cerebral Cancer
    Humle, Nanna
    Johnsen, Kasper Bendix
    Arendt, Gitte Abildgaard
    Nielsen, Rikke Paludan
    Moos, Torben
    Thomsen, Louiza Bohn
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (35) : 5487 - 5504
  • [25] Targeted delivery of a proapoptotic peptide to tumors in vivo
    Dufort, Sandrine
    Sancey, Lucie
    Hurbin, Amandine
    Foillard, Stephanie
    Boturyn, Didier
    Dumy, Pascal
    Coll, Jean-Luc
    JOURNAL OF DRUG TARGETING, 2011, 19 (07) : 582 - 588
  • [26] Targeted nonviral delivery of genome editors in vivo
    Tsuchida, Connor A.
    Wasko, Kevin M.
    Hamilton, Jennifer R.
    Doudna, Jennifer A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (11)
  • [27] In vivo Fate of Targeted Drug Delivery Carriers
    Zhao, Fan
    Wang, Jitong
    Zhang, Yu
    Hu, Jinru
    Li, Chenyang
    Liu, Shuainan
    Li, Ruixiang
    Du, Ruofei
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 : 6895 - 6929
  • [28] Strategies for targeted nonviral delivery of siRNAs in vivo
    Kim, Sang-Soo
    Garg, Himanshu
    Joshi, Anjali
    Manjunath, N.
    TRENDS IN MOLECULAR MEDICINE, 2009, 15 (11) : 491 - 500
  • [29] Targeted delivery of microRNA-126 to vascular endothelial cells via REDV peptide modified PEG-trimethyl chitosan
    Zhou, Fang
    Jia, Xiaoling
    Yang, Qingmao
    Yang, Yang
    Zhao, Yunhui
    Fan, Yubo
    Yuan, Xiaoyan
    BIOMATERIALS SCIENCE, 2016, 4 (05) : 849 - 856
  • [30] MODIFICATION OF THE ADENOVIRUS FIBER PROTEIN FOR TARGETED GENE DELIVERY
    MCCLELLAND, A
    STEVENSON, SC
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 411 - 411